Anika Therapeutics Stock
Anika Therapeutics Stock
Anika Therapeutics gained 2.630% today.
Anika Therapeutics is currently one of the favorites of our community with 9 Buy predictions and no Sell predictions.
With a target price of 15 € there is a hugely positive potential of 92.31% for Anika Therapeutics compared to the current price of 7.8 €.
Our community identified positive and negative aspects for Anika Therapeutics stock for the coming years. 1 users see the criterium "Brand" as a plus for the Anika Therapeutics stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Anika Therapeutics in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Anika Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Anika Therapeutics | 2.630% | -3.185% | -5.000% | -52.201% | -5.000% | -72.857% | -76.398% |
| Ardelyx Inc. | -0.500% | 11.247% | 35.898% | 39.208% | 37.337% | 133.587% | 16.350% |
| Evolus Inc | 2.910% | -3.318% | -32.562% | -67.360% | -25.138% | -56.825% | -12.559% |
| Champions Oncology Inc | 2.610% | -4.167% | 0.000% | -42.500% | -0.862% | 43.750% | -37.158% |
Comments
Anika Therapeutics (NASDAQ:ANIK) had its price target raised by analysts at Barrington Research from $15.00 to $16.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ANIK provided by MarketBeat
Anika Therapeutics (NASDAQ:ANIK) had its "outperform" rating reaffirmed by analysts at Barrington Research. They now have a $15.00 price target on the stock.
Show more
Ratings data for ANIK provided by MarketBeat
Anika Therapeutics Inc. (NASDAQ: ANIK) had its price target lowered by analysts at Barrington Research from $19.00 to $15.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ANIK provided by MarketBeat
News
Anika (ANIK) Q2 Revenue Beats by 4%
Anika Therapeutics (NASDAQ:ANIK), a medical technology company focused on joint preservation and regenerative therapy products, released its earnings on July 30, 2025. The key news from the release
